Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy

Abstract

Tyrosine kinase inhibitors (TKI) effective for the therapy of chronic myeloid leukemia are known to be associated with defective platelet function. Dasatinib, a potent inhibitor of BCR-ABL1 and SRC family kinases (SFK), is known to cause aberrant platelet function and can induce bleeding,